TR201905814T4 - Jak inhibitörü olarak bipirazol tuzu. - Google Patents

Jak inhibitörü olarak bipirazol tuzu.

Info

Publication number
TR201905814T4
TR201905814T4 TR2019/05814T TR201905814T TR201905814T4 TR 201905814 T4 TR201905814 T4 TR 201905814T4 TR 2019/05814 T TR2019/05814 T TR 2019/05814T TR 201905814 T TR201905814 T TR 201905814T TR 201905814 T4 TR201905814 T4 TR 201905814T4
Authority
TR
Turkey
Prior art keywords
biprazole
jack
inhibitor
salt
jak
Prior art date
Application number
TR2019/05814T
Other languages
English (en)
Inventor
Li Yun-Long
Zhuo Jincong
Qian Ding-Quan
Mei Song
Cao Ganfeng
Pan Yongchun
Li Qun
Jia Zhongjiang
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of TR201905814T4 publication Critical patent/TR201905814T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Mevcut buluş, Formül I: Bileşimi veya bunun farmasötik olarak kabul edilebilir tuzlarının yanı sıra, Janus kinaz (JAK) aktivitesini inhibe eden ve örneğin inflamatuar bozukluklar, otoimmün bozukluklar, kanser ve başka hastalıkları kapsayan, JAK aktivitesiyle ilgili hastalıkların tedavisinde faydalı olan bipirazol türevlerinin yanı sıra bunların bileşimleri ve kullanım metotlarını sağlamaktadır.
TR2019/05814T 2013-05-17 2014-05-16 Jak inhibitörü olarak bipirazol tuzu. TR201905814T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
TR201905814T4 true TR201905814T4 (tr) 2019-05-21

Family

ID=50983151

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05814T TR201905814T4 (tr) 2013-05-17 2014-05-16 Jak inhibitörü olarak bipirazol tuzu.

Country Status (36)

Country Link
US (8) US9382231B2 (tr)
EP (6) EP3231801B1 (tr)
JP (5) JP6415543B2 (tr)
KR (4) KR102442747B1 (tr)
CN (2) CN107698569B (tr)
AR (2) AR096330A1 (tr)
AU (5) AU2014265279B2 (tr)
BR (1) BR112015028501B8 (tr)
CA (1) CA2911536C (tr)
CL (1) CL2015003355A1 (tr)
CR (2) CR20190156A (tr)
CY (3) CY1119105T1 (tr)
DK (4) DK3786162T3 (tr)
EA (2) EA039660B1 (tr)
ES (5) ES2626793T3 (tr)
FI (2) FI3786162T3 (tr)
HK (1) HK1245769B (tr)
HR (5) HRP20231048T1 (tr)
HU (5) HUE073609T2 (tr)
IL (4) IL242453B (tr)
LT (5) LT3527263T (tr)
ME (2) ME02763B (tr)
MX (2) MX385187B (tr)
MY (1) MY174788A (tr)
PE (2) PE20200527A1 (tr)
PH (2) PH12015502563B1 (tr)
PL (5) PL3527263T3 (tr)
PT (5) PT2997023T (tr)
RS (5) RS64591B1 (tr)
SG (2) SG10201709469SA (tr)
SI (5) SI3527263T1 (tr)
SM (5) SMT202500397T1 (tr)
TR (1) TR201905814T4 (tr)
TW (4) TWI719401B (tr)
UA (1) UA117830C2 (tr)
WO (1) WO2014186706A1 (tr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JP6359546B2 (ja) 2012-11-01 2018-07-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
PE20200527A1 (es) 2013-05-17 2020-03-09 Incyte Corp Derivados del bipirazol como inhibidores jak
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
SG10201807952PA (en) * 2014-02-28 2018-10-30 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
CN106413716B (zh) 2014-04-08 2020-03-27 因赛特公司 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
BR112016025427A2 (pt) 2014-04-30 2017-08-15 Incyte Corp processos de preparação de um inibidor de jak1 e formas do mesmo
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
KR20190045302A (ko) * 2016-09-06 2019-05-02 에프. 호프만-라 로슈 아게 8-(아제티딘-1-일)-[1,2,4]트라이아졸로[1,5-a]피리딘일 화합물 및 이의 조성물 및 사용 방법
AU2018350980C1 (en) 2017-10-18 2024-12-12 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション （１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
UA127519C2 (uk) 2018-02-16 2023-09-20 Інсайт Корпорейшн Інгібітори шляху jak1, призначені для лікування порушень, пов'язаних із цитокінами
JP7565798B2 (ja) 2018-03-30 2024-10-11 インサイト・コーポレイション 炎症性皮膚疾患のバイオマーカー
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
MX2020010815A (es) 2018-04-13 2020-12-11 Incyte Corp Biomarcadores para enfermedad de injerto contra hospedero.
CN108484468A (zh) * 2018-05-11 2018-09-04 南京大学 芳基氮杂环丁烷类化合物的制备方法
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
EA202191170A1 (ru) 2018-10-31 2021-07-27 Инсайт Корпорейшн Комбинированная терапия для лечения гематологических заболеваний
US11596632B2 (en) 2018-12-19 2023-03-07 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
PH12021552130A1 (en) 2019-03-05 2022-08-31 Incyte Corp Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
TW202102222A (zh) 2019-03-19 2021-01-16 美商英塞特公司 白斑病之生物標記物
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4041204A1 (en) 2019-10-10 2022-08-17 Incyte Corporation Biomarkers for graft-versus-host disease
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP7518900B2 (ja) * 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
JP7802696B2 (ja) 2020-06-02 2026-01-20 インサイト・コーポレイション Ｊａｋ１阻害剤の調製プロセス
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022040172A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
CR20230129A (es) 2020-08-18 2023-07-13 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
ES3025481T3 (en) 2020-12-04 2025-06-09 Incyte Corp Jak inhibitor with a vitamin d analog for treatment of skin diseases
JP2023552452A (ja) * 2020-12-08 2023-12-15 インサイト・コーポレイション 白斑治療用のｊａｋ１経路阻害薬
CN112933095A (zh) * 2020-12-29 2021-06-11 上海岸阔医药科技有限公司 预防或治疗egfr功能异常相关的副作用的方法
TW202241439A (zh) * 2020-12-29 2022-11-01 大陸商上海岸闊醫藥科技有限公司 治療與抗腫瘤劑相關的皮膚疾病或病症的試劑和方法
TW202237083A (zh) 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法
EP4696710A3 (en) 2021-05-03 2026-05-06 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
CA3226714A1 (en) 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors
US20240307353A1 (en) 2023-03-16 2024-09-19 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
CN117186078A (zh) * 2023-11-06 2023-12-08 药康众拓(北京)医药科技有限公司 氘代氮杂环丁烷类jak抑制剂药物及用途
US20250325664A1 (en) 2024-04-22 2025-10-23 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株式会社 室外後写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株式会社ブリヂストン 空気ばね
JPH0515775Y2 (tr) 1987-07-13 1993-04-26
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
AU2002337142B2 (en) 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
IL161156A0 (en) 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX2010005300A (es) * 2007-11-16 2010-06-25 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus.
TWI444382B (zh) 2008-03-11 2014-07-11 Incyte Corp 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
PE20211639A1 (es) 2009-01-15 2021-08-24 Incyte Holdings Corp Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2012004180A (es) 2009-10-09 2012-07-17 Incyte Corp Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo.
CA2790070C (en) 2010-02-18 2018-03-06 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP2013523884A (ja) * 2010-04-14 2013-06-17 アレイ バイオファーマ、インコーポレイテッド ＪＡＫキナーゼの阻害剤としての５，７置換イミダゾ［１，２−ｃ］ピリミジン
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012076063A1 (en) * 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012116248A1 (en) 2011-02-24 2012-08-30 Massachusetts Institute Of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
MY165963A (en) * 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EP2758389B1 (en) 2011-09-22 2017-06-07 Merck Sharp & Dohme Corp. Pyrazole carboxamides as janus kinase inhibitors
TW201406761A (zh) * 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JP6359546B2 (ja) 2012-11-01 2018-07-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
PE20200527A1 (es) 2013-05-17 2020-03-09 Incyte Corp Derivados del bipirazol como inhibidores jak
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EA201592126A1 (ru) 2013-05-17 2016-05-31 Ф. Хоффманн-Ля Рош Аг 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
JO3583B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
SG10201807952PA (en) 2014-02-28 2018-10-30 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
BR112016025427A2 (pt) 2014-04-30 2017-08-15 Incyte Corp processos de preparação de um inibidor de jak1 e formas do mesmo
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CU24443B1 (es) 2014-12-16 2019-10-04 Novartis Ag COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
UA127519C2 (uk) 2018-02-16 2023-09-20 Інсайт Корпорейшн Інгібітори шляху jak1, призначені для лікування порушень, пов'язаних із цитокінами
JP7802696B2 (ja) 2020-06-02 2026-01-20 インサイト・コーポレイション Ｊａｋ１阻害剤の調製プロセス
ES3025481T3 (en) 2020-12-04 2025-06-09 Incyte Corp Jak inhibitor with a vitamin d analog for treatment of skin diseases
JP2023552452A (ja) 2020-12-08 2023-12-15 インサイト・コーポレイション 白斑治療用のｊａｋ１経路阻害薬

Also Published As

Publication number Publication date
IL287313B (en) 2022-03-01
HRP20170795T1 (hr) 2017-08-25
CY1119105T1 (el) 2018-02-14
JP7126741B2 (ja) 2022-08-29
AU2014265279B2 (en) 2018-09-27
TW202116320A (zh) 2021-05-01
PH12015502563B1 (en) 2019-04-26
RS58743B1 (sr) 2019-06-28
MX385187B (es) 2025-03-14
SI2997023T1 (sl) 2017-07-31
SI3527263T1 (sl) 2021-05-31
DK3231801T3 (en) 2019-04-15
NZ753636A (en) 2020-11-27
CL2015003355A1 (es) 2016-05-27
HK1221466A1 (en) 2017-06-02
AU2020202000A1 (en) 2020-04-09
KR102729910B1 (ko) 2024-11-15
PL3527263T3 (pl) 2021-05-17
EP3231801B1 (en) 2019-02-13
AU2018223058A1 (en) 2018-09-20
PT4275756T (pt) 2025-10-31
TWI664176B (zh) 2019-07-01
DK4275756T3 (da) 2025-09-29
TW202432140A (zh) 2024-08-16
PT3231801T (pt) 2019-05-24
CY1123756T1 (el) 2022-05-27
EP2997023B9 (en) 2018-06-13
ES2960731T3 (es) 2024-03-06
HK1245769B (en) 2020-02-07
MX2020004506A (es) 2021-08-09
CN107698569B (zh) 2020-11-27
PT2997023T (pt) 2017-05-31
PL3786162T3 (pl) 2024-04-08
EP4275756A3 (en) 2024-02-07
MY174788A (en) 2020-05-14
ES2845210T3 (es) 2021-07-26
LT4275756T (lt) 2025-11-10
HUE053122T2 (hu) 2021-06-28
SI4275756T1 (sl) 2025-12-31
TW201512191A (zh) 2015-04-01
US11905275B2 (en) 2024-02-20
SMT202100040T1 (it) 2021-03-15
US9382231B2 (en) 2016-07-05
SMT202500397T1 (it) 2025-11-10
EP2997023B1 (en) 2017-03-22
HUE043573T2 (hu) 2019-08-28
LT3231801T (lt) 2019-08-12
SI3231801T1 (sl) 2019-05-31
RS67392B1 (sr) 2025-11-28
EA201592199A1 (ru) 2016-05-31
TWI885650B (zh) 2025-06-01
CA2911536A1 (en) 2014-11-20
EA039660B1 (ru) 2022-02-24
AU2014265279A1 (en) 2015-11-26
UA117830C2 (uk) 2018-10-10
US11001571B2 (en) 2021-05-11
HRP20210119T1 (hr) 2021-03-05
HRP20231048T1 (hr) 2023-12-22
EA202090291A3 (ru) 2020-06-30
RS56012B1 (sr) 2017-09-29
US20160289215A1 (en) 2016-10-06
HUE073609T2 (hu) 2026-01-28
MX373238B (es) 2020-05-08
AR118120A2 (es) 2021-09-22
PL4275756T3 (pl) 2026-01-26
FI3786162T3 (fi) 2023-10-02
NZ753638A (en) 2020-11-27
PT3786162T (pt) 2023-10-20
AU2018223058B2 (en) 2020-01-02
SG11201509180WA (en) 2015-12-30
PE20160126A1 (es) 2016-02-24
IL264409B (en) 2021-05-31
KR102442747B1 (ko) 2022-09-14
CN105452239A (zh) 2016-03-30
PH12018502125A1 (en) 2019-03-25
KR20220127371A (ko) 2022-09-19
NZ713999A (en) 2020-11-27
US11591318B2 (en) 2023-02-28
EA036448B1 (ru) 2020-11-11
US20140343030A1 (en) 2014-11-20
WO2014186706A1 (en) 2014-11-20
SI3786162T1 (sl) 2024-02-29
SMT202300352T1 (it) 2024-01-10
LT2997023T (lt) 2017-06-26
IL287313A (en) 2021-12-01
TW201940479A (zh) 2019-10-16
KR20240063187A (ko) 2024-05-10
AU2021202685B2 (en) 2022-11-17
US10435392B2 (en) 2019-10-08
FI4275756T3 (fi) 2025-10-20
NZ753639A (en) 2020-11-27
RS64591B1 (sr) 2023-10-31
EP3527263B1 (en) 2020-10-28
CA2911536C (en) 2021-07-20
KR102341908B1 (ko) 2021-12-23
BR112015028501B8 (pt) 2023-01-24
ME03355B (me) 2019-10-20
HUE033587T2 (hu) 2017-12-28
US20180312492A1 (en) 2018-11-01
AU2020202000B2 (en) 2021-03-11
DK3527263T3 (da) 2021-01-25
KR102663357B1 (ko) 2024-05-14
IL282644A (en) 2021-06-30
KR20160019905A (ko) 2016-02-22
SG10201709469SA (en) 2017-12-28
IL282644B (en) 2021-10-31
HUE063817T2 (hu) 2024-01-28
EP3527263A1 (en) 2019-08-21
EP4620528A2 (en) 2025-09-24
IL264409A (en) 2019-02-28
JP6415543B2 (ja) 2018-10-31
RS61482B1 (sr) 2021-03-31
US20240150327A1 (en) 2024-05-09
US20230159501A1 (en) 2023-05-25
EP3786162A1 (en) 2021-03-03
JP2019011364A (ja) 2019-01-24
US20200010456A1 (en) 2020-01-09
HRP20251220T1 (hr) 2025-12-05
US20250206726A1 (en) 2025-06-26
SMT201700258T1 (it) 2017-07-18
AU2021202685A1 (en) 2021-05-27
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
IL242453B (en) 2019-11-28
JP2022163162A (ja) 2022-10-25
HRP20190713T1 (hr) 2019-06-14
CN105452239B (zh) 2017-11-21
JP6775560B2 (ja) 2020-10-28
CY1121763T1 (el) 2020-07-31
US12247020B2 (en) 2025-03-11
JP2024105557A (ja) 2024-08-06
BR112015028501B1 (pt) 2022-11-01
CN107698569A (zh) 2018-02-16
ME02763B (me) 2018-01-20
EP4620528A3 (en) 2025-11-26
ES3047826T3 (en) 2025-12-05
JP2016519147A (ja) 2016-06-30
US20210238168A1 (en) 2021-08-05
NZ753637A (en) 2020-11-27
TWI719401B (zh) 2021-02-21
BR112015028501A2 (pt) 2017-07-25
ES2720073T3 (es) 2019-07-17
PH12015502563A1 (en) 2016-02-22
MX2015015738A (es) 2016-03-16
LT3527263T (lt) 2021-05-10
PT3527263T (pt) 2021-02-01
TWI840646B (zh) 2024-05-01
CR20190156A (es) 2019-05-16
AU2022263454A1 (en) 2022-12-08
PL2997023T3 (pl) 2017-08-31
KR20210120120A (ko) 2021-10-06
US9926301B2 (en) 2018-03-27
PE20200527A1 (es) 2020-03-09
CR20150633A (es) 2016-04-05
AU2022263454B2 (en) 2024-01-18
EP3231801A1 (en) 2017-10-18
EP4275756B1 (en) 2025-09-03
EP3786162B1 (en) 2023-08-09
DK3786162T3 (da) 2023-10-09
AR096330A1 (es) 2015-12-23
ES2626793T3 (es) 2017-07-26
EA202090291A2 (ru) 2020-05-31
EP2997023A1 (en) 2016-03-23
JP2021008493A (ja) 2021-01-28
SMT201900223T1 (it) 2019-07-11
EP4275756A2 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MD4666B1 (ro) Inhibitori ai Syk
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690094A1 (ru) Ингибиторы syk
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
TR201816379T4 (tr) DNA-PK inhibitörleri.
EA201690752A1 (ru) Ингибиторы g12c kras
EA201990833A1 (ru) Соединение пиридина
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201591628A1 (ru) Дейтерированный палбоциклиб
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
MY192305A (en) Bipyrazole derivatives as jak inhibitors
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak